📊 IMA Key Takeaways
Is ImageneBio, Inc. (IMA) a Good Investment?
ImageneBio is a pre-commercial biotech firm with an unsustainable cash burn model: $15.2M annual negative free cash flow against only $800K revenue. While the strong balance sheet ($76M cash, zero debt) provides runway and loss trends are improving, the company remains fundamentally unprofitable with zero revenue growth and no evidence of near-term commercialization. Current burn rate exhausts cash within ~5 years without meaningful revenue inflection.
ImageneBio has negligible revenue and extremely negative margins alongside heavy operating and free cash flow burn, indicating a pre-commercial profile with weak near-term fundamentals. A strong balance sheet with substantial cash and no debt provides roughly two years of runway, but without evidence of revenue traction or improving unit economics, downside fundamental risk remains elevated.
Why Buy ImageneBio, Inc. Stock? IMA Key Strengths
- Excellent financial health with $76M cash and zero long-term debt
- Strong liquidity position (18.39x current ratio) provides operational flexibility
- Improving profitability trend with net losses declining 13.4% YoY and EPS improving 56.4% YoY
- Robust liquidity ($94.5M cash) and 12.5x current ratio
- No debt; low liabilities vs. assets
- Low capex needs; sizable equity cushion
IMA Stock Risks: ImageneBio, Inc. Investment Risks
- Severe cash burn of $14.8M operating outflow against negligible $800K revenue is unsustainable
- Zero revenue growth YoY with minimal absolute revenue indicates pre-commercial stage with no near-term monetization
- Biological products sector carries high regulatory, clinical development, and execution risk with uncertain path to profitability
- Burn rate trajectory at current stage exhausts available cash within ~5 years without significant revenue generation
- Sustained operating losses and ~-$48M annual cash burn
- Minimal revenue (flat YoY) and no gross margin visibility
- Dilution risk to fund R&D/commercialization despite runway
Key Metrics to Watch
- Operating cash flow trend and absolute burn rate per quarter
- Revenue growth trajectory and evidence of clinical/commercial progress
- Cash balance runway relative to operating burn rate
- Insider buying/selling activity and capital raise activity
- Operating cash flow burn rate and cash runway
- Revenue growth and operating margin trend
ImageneBio, Inc. (IMA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 18.39x current ratio provides a solid financial cushion.
IMA Profit Margin, ROE & Profitability Analysis
IMA vs Healthcare Sector: How ImageneBio, Inc. Compares
How ImageneBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ImageneBio, Inc. Stock Overvalued? IMA Valuation Analysis 2026
Based on fundamental analysis, ImageneBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ImageneBio, Inc. Balance Sheet: IMA Debt, Cash & Liquidity
IMA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ImageneBio, Inc.'s revenue has declined by 89% over the 5-year period, indicating business contraction. The most recent EPS of $-22.10 indicates the company is currently unprofitable.
IMA Revenue Growth, EPS Growth & YoY Performance
IMA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $800.0K | -$6.1M | $-0.95 |
| Q3 2025 | $800.0K | -$3.2M | $-2.58 |
| Q3 2024 | $1.2M | -$10.2M | $-0.21 |
| Q2 2024 | $2.0M | -$13.7M | $-0.28 |
| Q1 2024 | $5.3M | -$14.2M | $-0.33 |
| Q3 2023 | $1.2M | -$14.2M | $-0.40 |
| Q2 2023 | $382.0K | -$14.2M | $-0.44 |
| Q1 2023 | $3.4M | -$14.2M | $-0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ImageneBio, Inc. Dividends, Buybacks & Capital Allocation
IMA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ImageneBio, Inc. (CIK: 0001835579)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMA
What is the AI rating for IMA?
ImageneBio, Inc. (IMA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMA's key strengths?
Claude: Excellent financial health with $76M cash and zero long-term debt. Strong liquidity position (18.39x current ratio) provides operational flexibility. ChatGPT: Robust liquidity ($94.5M cash) and 12.5x current ratio. No debt; low liabilities vs. assets.
What are the risks of investing in IMA?
Claude: Severe cash burn of $14.8M operating outflow against negligible $800K revenue is unsustainable. Zero revenue growth YoY with minimal absolute revenue indicates pre-commercial stage with no near-term monetization. ChatGPT: Sustained operating losses and ~-$48M annual cash burn. Minimal revenue (flat YoY) and no gross margin visibility.
What is IMA's revenue and growth?
ImageneBio, Inc. reported revenue of $800.0K.
Does IMA pay dividends?
ImageneBio, Inc. does not currently pay dividends.
Where can I find IMA SEC filings?
Official SEC filings for ImageneBio, Inc. (CIK: 0001835579) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMA's EPS?
ImageneBio, Inc. has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, ImageneBio, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMA stock overvalued or undervalued?
Valuation metrics for IMA: ROE of -8.6% (sector avg: 15%), net margin of -1,327.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMA stock in 2026?
Our dual AI analysis gives ImageneBio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMA's free cash flow?
ImageneBio, Inc.'s operating cash flow is $-14.8M, with capital expenditures of $414.0K. FCF margin is -1,901.8%.
How does IMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,327.4% (avg: 12%), ROE -8.6% (avg: 15%), current ratio 18.39 (avg: 2).